innosferaНаука и инновацииScience and Innovations1818-98572412-9372Издательский дом «Белорусская наука»10.29235/1818-9857-2023-04-77-83innosfera-425Research ArticleДИССЕРТАЦИОННЫЕ ИССЛЕДОВАНИЯDISSERTATION RESEARCHНаночастицы в терапии злокачественных новообразованийNanoparticles in the treatment of malignant neoplasmsСтановаяА.StanovayaA.

Алеся Становая, научный сотрудник лаборатории нанобиотехнологий, аспирант

Alesya Stanovaya

alesiastanovaya@gmail.comЖоглаВ.ZhoglaV.

Виктория Жогла, младший научный сотрудник лаборатории нанобиотехнологий, магистр биологических наук

Victoria Zhogla

victoriya.zhogla@gmail.comГалец-БуйИ.Galets-BuyI.

Инесса Галец-Буй, старший научный сотрудник лаборатории нанобиотехнологий, кандидат биологических наук

Inessa Galets-Buy

inessahalets@gmail.comЛозниковаС.LoznikovaS.

Светлана Лозникова, консультант, кандидат биологических наук

Svetlana Loznikova

s_loznikova@mail.ruЩербинД.ShcherbinD.

Дмитрий Щербин, заведующий лабораторией нанобиотехнологий, доктор биологических наук, доцент

Dmitry Shcherbin

shcharbin@lab.ibp.org.byИнститут биофизики и клеточной инженерии НАН БеларусиBelarusГосударственный комитет по науке и технологиям Республики БеларусьBelarus202315052023147783Copyright © Издательский дом «Белорусская наука», 20232023Издательский дом «Белорусская наука»Издательский дом «Белорусская наука»https://innosfera.belnauka.by/jour/about/submissions#copyrightNoticehttps://innosfera.belnauka.by/jour/article/view/425

Проникновение новых технологий в химию, биологию и медицину привело к созданию таких дисциплин, как нанотехнология и наномедицина – отраслей науки, в которых размеры объекта исследования приобретают критическое значение. В то же время, широкое применение наночастиц требует понимания фундаментальных механизмов их взаимодействия с биологическими системами. Это особенно важно для разработки новых способов лечения и диагностики с их помощью. Данный обзор посвящен использованию наночастиц в терапии злокачественных новообразований и созданию генно-терапевтических систем на их основе. Рассматриваются различные типы частиц и особенности их влияния, методы и способы их применения, а также связанные с этим проблемы и ограничения. Представлена характеристика клинических препаратов на основе наночастиц.

The penetration of new technologies into chemistry, biology and medicine has led to the creation of new disciplines - nanotechnology and nanomedicine, branches of science in which the size of the object of study becomes critical. At the same time, the widespread application of nanoparticles in biology and medicine requires an understanding of the fundamental mechanisms of their interaction with biological systems. This is especially important for the development of new methods of treatment and diagnosis with their help. The presented review is devoted to the use of nanoparticles in the treatment of malignant neoplasms and the creation of gene therapy systems based on them. The review considers various types of nanoparticles and features of their effect on malignant neoplasms, methods and techniques for using nanoparticles for the diagnosis and treatment of cancer, as well as related problems and limitations. The characteristics of clinical preparations based on nanoparticles are presented.

наночастицыракдиагностикалечениегенная терапияnanoparticlescancerdiagnosticstreatmentgene therapyДанная работа поддержана Государственным комитетом по науке и технологиям Республики Беларусь и Белорусским республиканским фондом фундаментальных исследований, гранты Б22УЗБ-003, Б22КИТГ-020, Б21АРМГ 002, Б21ТЮБ 001, Б21РМ 045, Б21M 001, грантом TUBITAK №220N178.ReferencesGlobal cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries / H.Sung[etal.] // CA: acancer journal for clinicians. 2021. Vol. 71. №3. P.209–249.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries / H.Sung[etal.] // CA: acancer journal for clinicians. 2021. Vol. 71. №3. P.209–249.Медведева И.В. Статистический ежегодник Республики Беларусь / редкол.: И.В. Медведева (отв. ред.) [и др.] // Национальный статистический комитет РБ.– Минск, 2020.Медведева И.В. Статистический ежегодник Республики Беларусь / редкол.: И.В. Медведева (отв. ред.) [и др.] // Национальный статистический комитет РБ.– Минск, 2020.S. C. Baetke. Applications of nanoparticles for diagnosis and therapy of cancer / S.C. Baetke, T. Lammers, F. Kiessling// Br.J. Radiol. 2015. Vol. 88. №1054. Р. 20150207.S. C. Baetke. Applications of nanoparticles for diagnosis and therapy of cancer / S.C. Baetke, T. Lammers, F. Kiessling// Br.J. Radiol. 2015. Vol. 88. №1054. Р. 20150207.Radio-photothermal therapy mediated by asingle compartment nanoplatform depletes tumor initiating cells and reduces lung metastasis in the orthotopic 4T1 breast tumor model / M.Zhou[etal.] // Nanoscale. 2015. Vol. 7. №46. P.19438–19447.Radio-photothermal therapy mediated by asingle compartment nanoplatform depletes tumor initiating cells and reduces lung metastasis in the orthotopic 4T1 breast tumor model / M.Zhou[etal.] // Nanoscale. 2015. Vol. 7. №46. P.19438–19447.Application of nanotechnology to cancer radiotherapy/ Y. Mi [etal.] // Cancer Nanotechnol. 2016. Vol. 7. №1. Р. 11Application of nanotechnology to cancer radiotherapy/ Y. Mi [etal.] // Cancer Nanotechnol. 2016. Vol. 7. №1. Р. 11Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles / K.M. Au[etal.] // ACS Nano. 2015. Vol. 9. №9. P.8976–8996.Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles / K.M. Au[etal.] // ACS Nano. 2015. Vol. 9. №9. P.8976–8996.Evaluation of antioxidant and anticancer activity of copper oxide nanoparticles synthesized using medicinally important plant extracts / D. Rehana[etal.] // Biomed. Pharmacother. 2017. Vol. 89. P.1067–1077.Evaluation of antioxidant and anticancer activity of copper oxide nanoparticles synthesized using medicinally important plant extracts / D. Rehana[etal.] // Biomed. Pharmacother. 2017. Vol. 89. P.1067–1077.Kummara S.Synthesis, characterization, biocompatible and anticancer activity of green and chemically synthesized silver nanoparticles – A comparative study/ S. Kummara, M.B.Patil, T. Uriah // Biomed. Pharmacother. 2016. Vol. 84. P.10–21.Kummara S.Synthesis, characterization, biocompatible and anticancer activity of green and chemically synthesized silver nanoparticles – A comparative study/ S. Kummara, M.B.Patil, T. Uriah // Biomed. Pharmacother. 2016. Vol. 84. P.10–21.Antimicrobial and anticancer activities of porous chitosan-alginate biosynthesized silver nanoparticles / J. Venkatesan [etal.] // Int. J. Biol. Macromol. 2017. Vol. 98. P.515–525.Antimicrobial and anticancer activities of porous chitosan-alginate biosynthesized silver nanoparticles / J. Venkatesan [etal.] // Int. J. Biol. Macromol. 2017. Vol. 98. P.515–525.The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: Dense shell G4 PPI / I.Franiak-Pietryga[etal.] // Mol. Pharm. 2013. Vol. 10. №6. P.2490–2501.The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: Dense shell G4 PPI / I.Franiak-Pietryga[etal.] // Mol. Pharm. 2013. Vol. 10. №6. P.2490–2501.Gorzkiewicz M. Dendrimers as nanocarriers for nucleoside analogues / M. Gorzkiewicz, B. Klajnert-Maculewicz // Eur. J.Pharm. Biopharm. 2017. Vol. 114. P.43–56.Gorzkiewicz M. Dendrimers as nanocarriers for nucleoside analogues / M. Gorzkiewicz, B. Klajnert-Maculewicz // Eur. J.Pharm. Biopharm. 2017. Vol. 114. P.43–56.Nanomedicine: Towards development of patient-friendly drug-delivery systems for oncological applications / R. Ranganathan [etal.] // Int J Nanomedicine. 2012. Vol. 7. P.1043–1060. 13. Nanodrug delivery in reversing multidrug resistance in cancer cells / S. Kapse-Mistry[etal.] // Front. Pharmacol. 2014. Vol. 5. Р. 159Nanomedicine: Towards development of patient-friendly drug-delivery systems for oncological applications / R. Ranganathan [etal.] // Int J Nanomedicine. 2012. Vol. 7. P.1043–1060. 13. Nanodrug delivery in reversing multidrug resistance in cancer cells / S. Kapse-Mistry[etal.] // Front. Pharmacol. 2014. Vol. 5. Р. 159Carbon Nanotubes in Cancer Therapy and Drug Delivery / A. Elhissi [et al.] // Emerging Nanotechnologies in Dentistry. 2012. P.347–363.Carbon Nanotubes in Cancer Therapy and Drug Delivery / A. Elhissi [et al.] // Emerging Nanotechnologies in Dentistry. 2012. P.347–363.Folate and iron difunctionalized multiwall carbon nanotubes as dual-targeted drug nanocarrier to cancer cells / R.Li [etal.] // Carbon. 2011. Vol. 49. №5. P.1797–1805.Folate and iron difunctionalized multiwall carbon nanotubes as dual-targeted drug nanocarrier to cancer cells / R.Li [etal.] // Carbon. 2011. Vol. 49. №5. P.1797–1805.Nanotube molecular transporters: Internalization of carbon nanotube-protein conjugates into mammalian cells / N. W.S. Kam [etal.] // J. Am.Chem. Soc. 2004. Vol. 126. №22. P.6850–6851.Nanotube molecular transporters: Internalization of carbon nanotube-protein conjugates into mammalian cells / N. W.S. Kam [etal.] // J. Am.Chem. Soc. 2004. Vol. 126. №22. P.6850–6851.Gene delivery nanoparticles to modulate angiogenesis / J. Kim [et al.] // Adv. Drug Deliv. Rev. 2017. Vol.119. P.20–43.Gene delivery nanoparticles to modulate angiogenesis / J. Kim [et al.] // Adv. Drug Deliv. Rev. 2017. Vol.119. P.20–43.K. Wang. Nanoparticles for cancer gene therapy: Recent advances, challenges, and strategies/ K.Wang, F.M. Kievit, M.Zhang// Pharmacol. Res. 2016. Vol. 114. P.56–66.K. Wang. Nanoparticles for cancer gene therapy: Recent advances, challenges, and strategies/ K.Wang, F.M. Kievit, M.Zhang// Pharmacol. Res. 2016. Vol. 114. P.56–66.Ovarian cancer treatment with atumor-targeting and gene expression-controllable lipoplex/ Z.Y. He[etal.] // Sci. Rep. 2016. Vol. 6. Р. 23764.Ovarian cancer treatment with atumor-targeting and gene expression-controllable lipoplex/ Z.Y. He[etal.] // Sci. Rep. 2016. Vol. 6. Р. 23764.First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors / B.Schultheis [etal.] // J.Clin. Oncol. 2014. Vol. 32. №36. P.4141–4148.First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors / B.Schultheis [etal.] // J.Clin. Oncol. 2014. Vol. 32. №36. P.4141–4148.

The authors declare that there are no conflicts of interest present.